Report Highlights

France Gastritis Treatment: Market Overview

The French gastritis treatment market is one of the most structurally regulated pharmaceutical markets in Western Europe, with the Haute Autorité de Santé (HAS) and the Caisse Nationale d'Assurance Maladie (CNAM) jointly controlling reimbursement eligibility and pricing for all gastritis-related therapeutics. In 2024, the market was valued at USD 1.84 billion, underpinned by a high prevalence of H. pylori infection estimated at 25–30% of the adult population and a documented rise in autoimmune and stress-related gastritis linked to post-COVID gastrointestinal sequelae. The market structure is dominated by prescription-grade proton pump inhibitors, which account for over 55% of total market revenue, while over-the-counter antacids and H2-receptor antagonists constitute the accessible but lower-value retail layer.

Government has been the dominant force in shaping market form: the Comité Économique des Produits de Santé (CEPS) negotiates list prices directly with manufacturers, and mandatory price reductions apply at two-year intervals post-launch under the framework established by the Code de la Sécurité Sociale. Private sector innovation has led in product differentiation, particularly in extended-release formulations and combination H. pylori eradication kits, but commercial success is contingent on HAS's Service Médical Rendu (SMR) and Amélioration du Service Médical Rendu (ASMR) ratings, which determine reimbursement rate and therefore effective market access. This dual dynamic — private R&D combined with state-controlled pricing — defines competitive behaviour throughout the French gastritis treatment landscape.

Policy-Driven Growth in French Gastritis Treatment

The primary legislative driver is France's Plan National Maladies Rares and its intersection with the Plan Cancer 2021–2030, which explicitly identifies chronic atrophic gastritis as a pre-cancerous condition requiring structured surveillance and treatment protocols funded under the national health insurance system. Under this programme, HAS issued updated guidelines in 2022 requiring gastroenterologists to document H. pylori eradication confirmation within 28 days of therapy completion, triggering a measurable increase in confirmatory urea breath test reimbursements and thereby expanding diagnostic-linked therapeutic demand. The mechanism operates through compulsory clinical pathway adherence: physicians who deviate from the protocol risk CNAM audit penalties, effectively mandating guideline-consistent prescribing behaviour.

A second major policy mechanism is the Ségur de la Santé reform package, enacted through the Loi de Financement de la Sécurité Sociale (LFSS) 2021, which allocated EUR 19 billion to modernise hospital infrastructure and digitise patient records. Within gastroenterology, this has accelerated adoption of electronic prescribing systems that embed HAS-approved gastritis treatment algorithms directly into clinical decision tools used in CHU (Centre Hospitalier Universitaire) networks, standardising quadruple therapy prescription patterns. A third mechanism is the CNAM's conventional agreements with general practitioners, which include pay-for-performance indicators (rémunération sur objectifs de santé publique, ROSP) rewarding H. pylori screening rates in at-risk populations over 45, directly linking GP income to increased gastritis detection and downstream treatment volume.

Regulatory Barriers and Compliance Costs

The most significant regulatory barrier to market entry is the ASMR rating process administered by HAS, through which new gastritis treatments must demonstrate clinical superiority over comparators to achieve an ASMR I–III rating and thereby qualify for premium pricing in CEPS negotiations. Products receiving ASMR IV or V ratings — indicating minor or no improvement — are subject to reference pricing aligned with the cheapest equivalent, effectively eliminating commercial margin for branded products. This process typically requires 18 to 24 months from market authorisation to final reimbursement decision, and costs for the dossier preparation, health economic modelling, and medico-economic studies required under HAS guidance regularly exceed EUR 2 million per submission for a mid-sized pharmaceutical company.

A secondary barrier is the Décret relatif aux spécialités pharmaceutiques générique (generic substitution decree), which mandates that pharmacists substitute branded PPIs with generics unless the prescriber explicitly marks the prescription "non substituable." While this reduces patient cost, it compresses branded revenues and forces originator companies to justify premium positioning through ongoing real-world evidence generation — an additional compliance burden administered through the CNAM's post-inscription studies (études post-inscription) framework. Local content rules, while not formally structured as domestic manufacturing mandates, are operationally enforced through preferential Agence Nationale de Sécurité du Médicament (ANSM) inspection scheduling for French-manufacturing-site holders, creating indirect supply chain pressure on non-EU manufacturers entering the gastritis therapeutics segment.

Policy-Created Opportunities in France

The LFSS 2024 introduced an expanded early access scheme (accès précoce) administered by HAS, allowing innovative gastritis treatments — particularly those targeting autoimmune gastritis or refractory H. pylori strains — to generate reimbursed revenue before formal marketing authorisation, provided the manufacturer demonstrates "presumption of innovative benefit." This creates a commercially significant window of six to twelve months of funded patient access, and companies such as Phathom Pharmaceuticals, developing vonoprazan-based therapies as potassium-competitive acid blockers, stand to benefit from this pathway as an alternative to the lengthy ASMR process. The policy opportunity is reinforced by CNAM data showing that refractory or recurrent gastritis cases cost the system EUR 340 million annually, motivating payer willingness to support superior alternatives.

A second opportunity is embedded in France's Ma Santé 2022 strategy and its successor framework, which accelerated the creation of Communautés Professionnelles Territoriales de Santé (CPTS) — territorially organised care communities that receive dedicated funding to manage chronic digestive conditions. CPTS structures create bundled procurement opportunities for gastritis disease management programmes, including patient education tools, screening kits, and first-line therapy supply contracts, that are negotiated regionally rather than through national CEPS channels, offering manufacturers a faster and more flexible commercial route. Approximately 980 CPTS were operational in France by end of 2024, collectively covering over 62% of the national population and representing a structurally underexploited commercial channel for gastritis treatment stakeholders.

Market at a Glance

Leading Market Participants

• Sanofi
• AstraZeneca
• Takeda Pharmaceutical
• Pfizer
• Abbott Laboratories
• Mayoly Spindler
• Bayer AG
• Menarini Group
• Ipsen
• Recordati

Regulatory and Policy Environment

The primary legislative framework governing gastritis treatment in France is the Code de la Santé Publique, supplemented by annual Lois de Financement de la Sécurité Sociale, which collectively define reimbursement eligibility, prescribing authorisation, and pharmacovigilance obligations for all gastroenterological products. The ANSM is the national competent authority for marketing authorisation, operating in parallel with the European Medicines Agency (EMA) for centrally authorised products. HAS issues and updates treatment guidelines, most recently in 2022 for H. pylori eradication protocols adopting bismuth-based quadruple therapy as first-line standard in response to rising clarithromycin resistance documented by the national HELICOBACTER surveillance network. France's reimbursement framework is notably more restrictive than Germany's AMNOG process in that post-ASMR pricing is binding from day one, with no free-pricing period allowed for outpatient gastritis treatments, making France's entry timeline among the most compliance-intensive in the EU5.

Upcoming regulatory changes expected before 2027 include mandatory real-world evidence submission requirements under the revised HAS guidelines for chronic disease therapeutics, which will require manufacturers of long-term PPI therapies to submit annual registry data to CNAM demonstrating sustained clinical benefit in the French treated population — a requirement with no direct equivalent in Spain or Italy. ANSM is also expected to finalise updated guidance on antimicrobial stewardship in H. pylori eradication by Q3 2026, which will likely restrict empirical clarithromycin-based triple therapy further and mandate susceptibility testing prior to regimen selection in CHU settings, reshaping prescribing patterns and shifting formulary demand toward bismuth quadruple and vonoprazan-based combination products across the hospital channel.

Long-Term Policy Outlook for French Gastritis Treatment

By 2032, the dominant policy force reshaping France's gastritis treatment market will be the full operational maturity of the Mon Espace Santé digital health platform, through which CNAM plans to integrate automated gastritis screening prompts for patients over 45 with confirmed NSAID use, family history of gastric cancer, or documented H. pylori serology. This algorithmic screening initiative, embedded in the France 2030 health digitalisation investment programme, is projected to increase annual new gastritis diagnoses by 8–12%, generating sustained pipeline demand for first-line therapeutics. Manufacturers who integrate their product data into the Mon Espace Santé prescribing ecosystem before 2027 will hold a structural information advantage over later entrants in the primary care prescribing channel.

The second major long-term policy shift is the anticipated revision of the CEPS conventional framework, expected around 2028, which is likely to introduce value-based pricing pilots for gastritis treatments demonstrating documented H. pylori eradication superiority — modelled on HAS's work on indication-specific pricing for oncology. This would allow manufacturers of vonoprazan-based combination therapies or next-generation mucosal protective agents to negotiate outcome-linked pricing above reference PPI rates, breaking the current price compression dynamic. Companies that invest in generating eradication rate registries in French CHU networks between 2025 and 2028 will be best positioned to satisfy the evidence requirements and capture premium pricing under the revised CEPS framework when it takes effect.

Market Segmentation

By Drug Class

• Proton Pump Inhibitors
• H2-Receptor Antagonists
• Antacids
• Antibiotics (H. pylori Eradication)
• Mucosal Protective Agents
• Potassium-Competitive Acid Blockers

By Gastritis Type

• H. pylori-Associated Gastritis
• Autoimmune Gastritis
• Chemical or Reactive Gastritis
• Stress-Induced Gastritis
• Atrophic Gastritis

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Outpatient Clinic

By End User

• Centre Hospitalier Universitaire
• Private Hospital
• General Practice Clinic
• Gastroenterology Specialist Centre
• Ambulatory Surgical Centre

Frequently Asked Questions

Q1. Which regulatory agency grants marketing authorisation for gastritis drugs in France? ▼

The Agence Nationale de Sécurité du Médicament (ANSM) grants national marketing authorisations, while the European Medicines Agency (EMA) handles centrally authorised products that are then recognised in France. Both pathways are required before a product can enter HAS reimbursement assessment.

Q2. How does HAS determine whether a gastritis treatment qualifies for reimbursement in France? ▼

HAS evaluates each product through its Service Médical Rendu (SMR) and Amélioration du Service Médical Rendu (ASMR) rating system, assessing clinical benefit and therapeutic improvement over existing standards. The ASMR rating directly determines the pricing ceiling CEPS applies in manufacturer negotiations.

Q3. What is the current first-line H. pylori eradication protocol mandated by French clinical guidelines? ▼

HAS guidelines updated in 2022 designate bismuth-based quadruple therapy — comprising a PPI, bismuth subcitrate, tetracycline, and metronidazole — as the first-line eradication protocol, replacing clarithromycin triple therapy due to documented resistance levels exceeding 20% nationally. Eradication confirmation within 28 days is now a required clinical pathway step.

Q4. What compliance obligations apply to manufacturers of long-term PPI therapies sold in France? ▼

Manufacturers must submit post-inscription real-world evidence studies to CNAM at intervals stipulated in the reimbursement agreement, demonstrating sustained clinical benefit in the French treated population. Failure to submit compliant registry data risks delisting or mandatory price reduction under Code de la Sécurité Sociale provisions.

Q5. How does France's early access scheme benefit gastritis treatment developers? ▼

The accès précoce pathway administered by HAS allows manufacturers to generate reimbursed revenue for innovative gastritis treatments before formal marketing authorisation, provided they demonstrate a presumption of innovative benefit. This creates a funded patient access window of six to twelve months, enabling commercial revenue generation and real-world data collection simultaneously.